Lilly to help Dutch biotech develop cancer therapies in deal worth up to $1.6B
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors